prikaz prve stranice dokumenta Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: a report from the EBMT activity survey
  Download
PDF 1.8 MB
Scientific paper - Original scientific paper
Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: a report from the EBMT activity survey
Bone Marrow Transplantation, 57 (2022), 5; 742-752. https://doi.org/10.1038/s41409-022-01604-x
(European Society for Blood and Marrow Transplantation (EBMT)) Passweg, Jakob R.; Baldomero, Helen; Chabannon, Christian; Corbacioglu, Selim; de la Cámara, Rafael; Dolstra, Harry; Glass, Bertram; Greco, Raffaella; Mohty, Mohamad; Neven, Bénédicte; Peffault de Latour, Régis; Perić, Zinaida; Snowden, John A.; Yakoub-Agha, Ibrahim; Sureda, Anna; Kröger, Nicolaus More authors...

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Passweg, J. R., Baldomero, H., Chabannon, C., Corbacioglu, S., de la Cámara, R., Dolstra, H. ... Kröger, N. (2022). Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: a report from the EBMT activity survey. Bone Marrow Transplantation, 57. (5), 742-752. doi: 10.1038/s41409-022-01604-x

Passweg, Jakob R., et al. "Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: a report from the EBMT activity survey." Bone Marrow Transplantation, vol. 57, no. 5, 2022, pp. 742-752. https://doi.org/10.1038/s41409-022-01604-x

Passweg, Jakob R., Helen Baldomero, Christian Chabannon, Selim Corbacioglu, Rafael de la Cámara, Harry Dolstra, Bertram Glass, et al. "Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: a report from the EBMT activity survey." Bone Marrow Transplantation 57, no. 5 (2022): 742-752. https://doi.org/10.1038/s41409-022-01604-x

Passweg, J. R., et al. (2022) 'Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: a report from the EBMT activity survey', Bone Marrow Transplantation, 57(5), pp. 742-752. doi: 10.1038/s41409-022-01604-x

Passweg JR, Baldomero H, Chabannon C, Corbacioglu S, de la Cámara R, Dolstra H, and sur.. Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: a report from the EBMT activity survey. Bone Marrow Transplantation [Internet]. 2022 May [cited 2024 December 02];57(5):742-752. doi: 10.1038/s41409-022-01604-x

J. R. Passweg, et al., "Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: a report from the EBMT activity survey", Bone Marrow Transplantation, vol. 57, no. 5, pp. 742-752, May 2022. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:376147. [Accessed: 02 December 2024]

Metadata
Title (english)Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: a report from the EBMT activity survey
AuthorJakob R. Passweg
AuthorHelen Baldomero
AuthorChristian Chabannon
AuthorSelim Corbacioglu
AuthorRafael de la Cámara
AuthorHarry Dolstra
AuthorBertram Glass
AuthorRaffaella Greco
AuthorMohamad Mohty
AuthorBénédicte Neven
AuthorRégis Peffault de Latour
AuthorZinaida Perić
AuthorJohn A. Snowden
AuthorIbrahim Yakoub-Agha
AuthorAnna Sureda
AuthorNicolaus Kröger
CollaborationEuropean Society for Blood and Marrow Transplantation (EBMT)
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Internal Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract (english)
Abstract In 2020, 45,364 HCT in 41,016 patients, 18,796 (41%) allogeneic and 26,568 (59%) autologous in 690 centers were reported. Changes observed were as follows: total number of HCT −6.5%, allogeneic HCT −5.1%, autologous HCT −7.5%, and were more pronounced in non-malignant disorders for allogeneic HCT and in autoimmune disease for autologous HCT. Main indications were myeloid malignancies 10,441 (25%), lymphoid malignancies 26,120 (64%) and non-malignant disorders 2532 (6%). A continued growth in CAR-T cellular therapies to 1874 (+65%) patients in 2020 was observed. In allogeneic HCT, the use of haploidentical donors increased while use of unrelated and sibling donors decreased. Cord blood HCT increased by 11.7% for the first time since 2012. There was a significant increase in the use of non-myeloablative but a drop in myeloablative conditioning and in use of marrow as stem cell source. We interpreted these changes as being due to the SARS-CoV-2 pandemic starting early in 2020 in Europe and provided additional data reflecting the varying impact of the pandemic across selected countries and larger cities. The transplant community confronted with the pandemic challenge, continued in providing patients access to treatment. This annual report of the EBMT reflects current activities useful for health care planning.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleBone Marrow Transplantation
Numberingvol. 57, no. 5, pp. 742-752
p-ISSN0268-3369
e-ISSN1476-5365
DOIhttps://doi.org/10.1038/s41409-022-01604-x
URN:NBNurn:nbn:hr:105:376147
Publication2022-05
Document URLhttps://www.nature.com/articles/s41409-022-01604-x
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2022-07-19 09:46:06